ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.81 - $5.48
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$33.33M
Enterprise Value$21.77M
Total Cash (Recent Filing)$745.83K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding25,440,407
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)4.46
Price to Sales (P/S)62.24
P/FCF Ratio-16.56
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit37.42
Enterprise Value/Ebitda-3.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Improved LeverageThe material improvement in leverage (debt-to-equity ~0.31 in 2025) meaningfully lowers near-term default and refinancing risk for a cash-burning clinical-stage biopharma. A stronger balance sheet provides more runway to advance trials or pursue out-licensing before urgent dilutive funding is required.
High Product Gross MarginsNear-100% gross margins indicate attractive unit economics for any eventual partnered or commercialized asset. If clinical candidates progress and scale via a partner, revenue could convert to high incremental profits, aiding long-term margin sustainability despite current high R&D and SG&A.
Governance And Retention ToolsRe-election of directors and an expanded equity incentive reserve strengthen governance continuity and talent retention capacity. For a small clinical-stage company, the ability to grant equity aids recruiting and aligning management and scientific teams to execute multi-year development programs and partnering negotiations.
Bears Say
Weak Cash GenerationThe company lacks consistent internal cash generation, with 2025 operating/free cash flow at $0 and prior years deeply negative. Persistent cash deficits force reliance on external capital, raising dilution and financing risk and constraining the firm's ability to fund clinical milestones independently over the medium term.
Tiny, Volatile Revenue BaseA minimal and unstable revenue base (roughly $0.8M in 2025, down 25% YoY) means operating costs are unrelated to sustainable commercial income. Until out-licensing or partnerships produce recurring revenue, the business model depends on episodic transactions and external financing, raising execution and cash runway risk.
Deep, Persistent LossesSevere and ongoing losses (net loss ~$5.9M in 2025 and ROE around -53%) erode shareholder equity and limit flexibility. Continued negative returns strain the balance sheet over time, increasing the probability of further equity raises or asset sales that can dilute investors and hinder long-term strategic optionality.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.81 and its highest was $5.48 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $33.33M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 214 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 25,440,407 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ABVC BioPharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
447.44%
12-Months-Change
Fundamentals
Return on Equity
-88.89%
Trailing 12-Months
Asset Growth
179.34%
Trailing 12-Months
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.40% Mutual Funds
0.05% Other Institutional Investors
97.77% Public Companies and
Individual Investors